Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 ...

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

A 4-year, $1.6 million grant will allow the university to expand programs designed to equip health care providers to respond ...

Attorney General William Tong announced the settlement Wednesday with nurse Dayna Giordano and her medical office for ...

The Connecticut attorney general’s office said numerous doses of drugs that were never administered were billed to Medicaid.

The nurse did not seek or receive payment for the drugs, officials said, but wasted taxpayer money and medication due to "poor record-keeping." ...

Indivior PLC today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses ...

Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe OUD. A previous study cited by the study authors had suggested that a higher ...

Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...